Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
La Oficina de Propiedad Intelectual de la Unión Europea (EUIPO) reabre los Bonos 1 (IP Scan y IP Scan Enforcement), 2 (Marcas y Diseños) y 3 (patentes) del SME Fund para pymes y emprendedores, que pueden solicitar las ayudas desde el 20 de octubre de 2025.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
155
resultados
Última actualización
29/11/2025 [07:09:00]
Resumen de: US2025360273A1
An insulin infusion system is provided with a manual insertion device having a dual retraction spring (230) configuration for automatic introducer needle (222) retraction. A button (200) of the insertion device is used to insert the introducer needle (222) and catheter (202), and once the introducer needle (222) and catheter (202) have been fully inserted, a rotating engagement releases the dual retraction springs (230) such that the introducer needle (222) automatically retracts, leaving the catheter (202) in the body of the user. An end of the introducer needle (222) remains in the inserted catheter (202) and/or in the septum (206) of the inserted catheter (202) to provide an uninterrupted fluid path.
Resumen de: WO2025244151A1
The present invention relates to a non-invasive glucose measurement device and method. To this end, the non-invasive glucose measurement device according to one embodiment of the present invention may comprise: a light irradiation unit which is positioned beneath an inner lower case disposed beneath an inserted finger, and which includes a first light-emitting element and a second light-emitting element for irradiating light toward the finger placed on the inner lower case; a light reception unit which is disposed on an inner upper case disposed on the finger, and which includes a first light-receiving element and a second light-receiving element for receiving the light irradiated from the light irradiation unit and transmitted through the finger; a motor unit including a first motor disposed at one side of the inner lower case and a second motor disposed at the other side of the inner lower case; a pressure sensor unit which is disposed beneath the inner lower case, and which includes a first pressure sensor and a second pressure sensor for measuring pressure applied by the finger; and a processor for measuring glucose by using the amount of light received through the light reception unit.
Resumen de: US2025359790A1
A continuous glucose monitoring system may utilize externally sourced information regarding the physiological state and ambient environment of its user for externally calibrating sensor glucose measurements. Externally sourced factory calibration information may be utilized, where the information is generated by comparing metrics obtained from the data used to generate the sensor's glucose sensing algorithm to similar data obtained from each batch of sensors to be used with the algorithm in the future. The output sensor glucose value of a glucose sensor may also be estimated by analytically optimizing input sensor signals to accurately correct for changes in sensitivity, run-in time, glucose current dips, and other variable sensor wear effects. Correction actors, fusion algorithms, EIS, and advanced ASICs may be used to implement the foregoing, thereby achieving the goal of improved accuracy and reliability without the need for blood-glucose calibration, and providing a calibration-free, or near calibration-free, sensor.
Resumen de: US2025364143A1
A method for determination of an event-related index for a human user, where:one provides time-based data for an observation period, with:time-based blood glucose data for the totality of the observation period, said time-based blood glucose data being derived from a continuous glucose monitor,time-based event data for the event period,a computerized index determination module determines said event-related index as a composite index of the blood glucose data related to the event period and the blood glucose data outside the event period.
Resumen de: US2025359828A1
The technologies discussed herein relate to a biometrics system comprising one or more processors, computer storage memory having computer-executable instructions, surgically implantable devices, and wearables (e.g., an apparel item configured for an upper torso, an apparel item configured for a lower torso, a sock, a headband, other types of wearables, or one or more combinations thereof) having one or more biometric sensors (e.g., a heart rate sensor, a sweat sensor, a glucose sensor, other types of biometric sensors, or one or more combinations thereof) and one or more sensation devices (e.g., a plurality of visible light sources, a haptic feedback device, other types of sensation devices, or one or more combinations thereof). The wearables may also include one or more environmental sensors. The wearables emulate, transmogrify, or enhance one or more human senses using the one or more sensation devices based on biometric data or environmental data received.
Resumen de: US2025359762A1
Near Infrared Spectroscopy is employed to non-invasively detect blood glucose concentrations, in a multi-sensing detection device. A multi-layered artificial neural network is used to assess these relationships of non-linear interference from human tissue, as well as differences among individuals, and accurately estimate blood glucose levels. Diffuse reflectance spectrum from the palm at six different wavelengths analyzed with a neural network, results in a correlation coefficient as high as 0.9216 when compared to a standard electrochemical glucose analysis test.
Resumen de: EP4653033A1
Provided is a safety insulin pen needle. The safety insulin pen needle includes a needle hub, a protective sleeve, a needle cap, and a limiting block. A fixed post protruding along with an injection needle is disposed on the needle hub. A snap-fit step is disposed on the surface of the fixed post. The injection needle is inserted through the protective sleeve. A spring is clamped between the protective sleeve and the needle hub such that the protective sleeve is axially movable relative to the needle hub to expose or cover a needle tip of the injection needle. A protruding edge is disposed on an outer wall of the protective sleeve. A first limiting step and a second limiting step are disposed on an inner wall of the protective sleeve along a direction in which the injection needle penetrates. The inner diameter of the second limiting step is smaller than the inner diameter of the first limiting step. The needle cap is fixedly assembled with the needle hub and encloses the protective sleeve within the needle cap. The needle cap is provided with a through-hole allowing the protective sleeve to extend out. The through-hole limits the protruding edge. The limiting block is located in an inner cavity of the protective sleeve and is sleeved on the injection needle. A first end of the limiting block is provided with a claw that engages with the snap-fit step, and a second end of the limiting block cooperates with the first limiting step or the second limiting step to stop the protec
Resumen de: AU2025223826A1
A sensor applicator assembly for a continuous glucose monitoring system is provided. The sensor applicator assembly is assembled as a single unitary product in which a sensor module measuring a blood glucose level is preinstalled in an applicator, such that the sensor module is ejected by an operation of the applicator to be attached to a human body. The applicator includes a main container and a plunger body fixedly coupled to a first position within the main container. The plunger body is configured to be decoupled from the first position and to be moved to a second position in an injecting direction. The sensor module is coupled to one end portion of the plunger body to be moved integrally with the plunger body as the plunger body being moved toward the second position. An adhesive layer is attached to a lower surface of the sensor module to attach the sensor module to the human body, and is configured to be moved together with the sensor module as the plunger body being moved toward the second position. A sensor applicator assembly for a continuous glucose monitoring system is provided. The sensor applicator assembly is assembled as a single unitary product in which a sensor module measuring a blood glucose level is preinstalled in an applicator, such that the sensor module is ejected by an operation of the applicator to be attached to a human body. The applicator includes a main container and a plunger body fixedly coupled to a first position within the main container. T
Resumen de: US2025353905A1
The present invention provides compositions and methods for treating Postural orthostatic tachycardia syndrome (POTS). In some embodiments, the POTS is associated with hypermobility spectrum disorders/hypermobile Ehlers-Danlos syndrome (HSD/hEDS). In various embodiments, the invention relates to administering a composition comprising an effective amount of a molecular antagonist of Glucose-dependent Insulinotropic Polpeptide (GIP) to a patient in need thereof. In various embodiments, the molecular antagonist can be provided in a form for convenient self-administration upon the onset of symptoms or to prevent or reduce postprandial POTS symptoms, or in other embodiments, is administered at a set frequency.
Resumen de: US2025356983A1
An apparatus for optimizing a patient's insulin dosage regimen over time, comprising: at least a first computer-readable memory for storing data inputs corresponding at least to one or more components in a patient's present insulin dosage regimen and the patient's blood-glucose-level measurements determined at a plurality of times; a processor operatively connected to the at least first computer-readable memory, the processor programmed at least to determine from the data inputs corresponding to the patient's blood-glucose-level measurements determined at a plurality of times whether and by how much to vary at least one of the one or more components of the patient's present insulin dosage regimen in order to maintain the patient's future blood-glucose-level measurements within a predefined range; and a display operative to display information corresponding to at least the patient's present insulin dosage regimen.
Resumen de: AU2025259998A1
Method, device and system for providing consistent and reliable glucose response information to physiological changes and/or activities is provided to improve glycemic control and health management. Method, device and system for providing consistent and reliable glucose response information to physiological changes and/or activities is provided to improve glycemic control and health management. ov o v
Resumen de: AU2025259892A1
(57) Abstract: A wearable device for non-invasive monitoring of the presence, amount, and/or concentration of an analyte in a sample from a user of the device is described. The analyte is selected to be indicative of or related to a physiological status of a user. Relevant physiological status include hypoglycemia, infection, respiratory infection, urinary infection, gastrointestinal infection, obesity, diabetes, type I diabetes and type II diabetes. (57) Abstract: A wearable device for non-invasive monitoring of the presence, amount, and/or concentration of an analyte in a sample from a user of the device is described. The analyte is selected to be indicative of or related to a physiological status of a user. Relevant physiological status include hypoglycemia, infection, respiratory infection, urinary infection, gastrointestinal infection, obesity, diabetes, type I diabetes and type II diabetes. ct c t
Resumen de: AU2024252061A1
Methods and devices include predicting future glucose and engagement levels for a user by receiving the user's glucose levels collected by a continuous glucose monitoring (CGM) device over a time period, receiving engagement data associated with the user, wherein the engagement data are associated with the user's medication intake, diet, physical activity, laboratory results, and education activity, determining a first glycemia risk index (GRI) value, determining, using a machine learning model and responsive to the user's glucose levels and the engagement data collected over the time period, one or more predictions for future glucose levels for the user including a prediction that a future GRI value is greater than or less than the first GRI value, and determining, using the machine learning model and responsive to the user's engagement data collected over the time period, one or more predictions for future engagement levels.
Resumen de: US2025352731A1
Medication delivery methods, devices and systems are provided, the medication delivery device includes user interface elements, control circuitry, and a memory. The method includes receiving analyte measurement data of a user, presenting information related to the analyte measurement data to the user, and determining an intended dose of medication based on at least one of the analyte measurement data, optionally, therapeutic relevant conditions, therapy parameters, or a calculated insulin-on-board (IOB) value. When the user is queried to indicate that the user is ready for the delivery without presenting the intended dose on any of the one or more user interface elements of the medication delivery device, the intended dose is automatically delivered after receiving the user's indication.
Resumen de: US2025352092A1
Disclosed herein are techniques for blood glucose management. In one example, a processor-implemented method includes receiving an input of a target value of a first continuous glucose monitoring (CGM) metric, estimating a target value of at least a second CGM metric that corresponds to the target value of the first CGM metric, and providing the estimated target value of at least the second CGM metric to a user. In some examples, the processor-implemented method also includes determining that the estimated target value of at least the second CGM metric meets a predetermined criterion, and configuring an insulin delivery system based on the target value of the first CGM metric.
Resumen de: US2025352094A1
An integrated glucose monitoring system comprising a glucometer and mobile device housed in a housing. The glucometer includes a measurement component to receive a blood glucose test strip containing a sample of blood of an individual, and a port to transmit the blood glucose measurement to a mobile device. The mobile device communicatively and physically coupled to the glucometer. The mobile device includes a port configured to couple with the glucometer, a communication component to receive the blood glucose measurement from glucometer, a power management component to transmit power to the glucometer, and another port to receive power from a power source to power the mobile device. The housing is to house the glucometer and the mobile device to form a single solitary glucose monitoring system.
Resumen de: US2025352127A1
The subject matter of the present disclosure generally relates to techniques for neuromodulation that include applying energy (e.g., ultrasound energy) into the tissue to cause a change in a glucose transporter pathway molecule and/or an incretin pathway molecule. In one embodiment, the neuromodulation is performed as a treatment of a metabolic disorder.
Resumen de: US2025352737A1
A device and product to prepare and numb the skin of a user prior to the insertion of a sensor or canula under the skin. The invention is an applicator and one or more products dispensed thereby or disposed or positioned thereon, the applicator operable to apply a first product and in some cases, a second product, to the skin. The applicator is further operable to dry the skin so as to allow an adhesive backing of a device to be attached to the skin. Preferably, the invention is used to prepare and numb the skin prior to receiving a sensor from a continuous glucose monitor (CGM) or a canula from a insulin pump.
Resumen de: WO2025239063A1
This blood glucose level measurement device comprises: a light output unit that outputs light; a light detection unit that detects light that has been output by the light output unit and passed through a living body; a temporal phase difference calculation unit that, on the basis of the detection result of the light detection unit, calculates the temporal phase difference between an oxygenated hemoglobin waveform pertaining to the oxygenated hemoglobin concentration of the blood of the living body and a deoxygenated hemoglobin waveform pertaining to the deoxygenated hemoglobin concentration of the blood of the living body; a blood glucose level calculation unit that calculates the blood glucose level of the living body on the basis of the calculated temporal phase difference; a level of similarity estimation unit that estimates the level of waveform similarity between the oxygenated hemoglobin waveform and the deoxygenated hemoglobin waveform; and a reliability estimation unit that estimates the reliability of the calculated blood glucose level. The reliability estimation unit estimates that the reliability becomes smaller as the level of waveform similarity becomes smaller.
Resumen de: US2025352093A1
The present disclosure relates to a continuous glucose monitoring device. The present disclosure provides a continuous glucose monitoring device wherein: a body attachment unit is manufactured in the state in which the body attachment unit is assembled in an applicator, and thus a user's additional work for attaching the body attachment unit to the body is minimized and the body attachment unit can be attached to the body by simply operating the applicator; in particular, a wireless communication chip is disposed in the body attachment unit so as to communicate with an external terminal, and thus simple and convenient use can be achieved without any additional work for connection of a separate transmitter and maintenance and management can also be easily performed; and the monitoring operation is started by the user's manipulation after the body attachment unit is attached to the body, and thus the user can adjust the operation start time to an appropriate point as necessary and the operation can be started in a stabilized state so as to enable more accurate glucose monitoring.
Resumen de: US2025352095A1
The present disclosure relates to a continuous blood sugar measuring device, and provides a continuous blood sugar measuring device which is capable of minimizing additional work of a user in order to attach a body attachment unit, by manufacturing the body attachment unit to be assembled inside an applicator so that the body attachment unit can be attached to the body simply by operating the applicator and, particularly: communicating with an external terminal by providing a wireless communication chip in the body attachment unit so that simple and convenient use is possible and maintenance can easily be performed without the additional work of connecting a separate transmitter; initiating operation by a manipulation of the user, after attaching the body attachment unit to the body, so that an operation initiation time can be adjusted to a suitable time according to the need of the user; and initiating operation in a stabilized state to enable a more accurate measurement of blood sugar.
Resumen de: US2025352726A1
A control device (30) for determining a recommendation value of a control parameter of an insulin infusion device (20).
Resumen de: EP4649888A2
Methods and devices to monitor an analyte in body fluid are provided. Embodiments include continuous or discrete acquisition of analyte related data from a transcutaneously positioned in vivo analyte sensor automatically or upon request from a user. The detection and/or monitoring of glucose levels or other analytes, such as lactate, oxygen, AIC, or the like, in certain individuals is vitally important to their health. For example, the monitoring of glucose is particularly important to individuals with diabetes.
Resumen de: EP4651146A1
Disclosed herein are techniques for blood glucose management. In one example, a processor-implemented method includes receiving an input of a target value of a first continuous glucose monitoring (CGM) metric, estimating a target value of at least a second CGM metric that corresponds to the target value of the first CGM metric, and providing the estimated target value of at least the second CGM metric to a user. In some examples, the processor-implemented method also includes determining that the estimated target value of at least the second CGM metric meets a predetermined criterion, and configuring an insulin delivery system based on the target value of the first CGM metric.
Nº publicación: US12471808B1 18/11/2025
Solicitante:
UNIV SOUTH FLORIDA [US]
University of South Florida
Resumen de: US12471808B1
A system and method for continuous glucose monitoring (CGM) of blood in a blood vessel of a patient using a non-invasive sensor composed of a patch antenna operating in the Industrial, Scientific and Medical (ISM) Radio band (5.725 GHz-5.875 GHz). The device determines the blood glucose concentration of the blood in the blood vessel based on the measured shift of the resonant frequency of the non-invasive antenna patch sensor. A radio frequency (RF) synthesizer is used to drive the patch antenna with a fraction of its output coupled to both the antenna and receiver through a directional coupler. In this approach both the transmitted (FWD) and received (REV) power are processed, by demodulating logarithmic amplifiers, which convert the RF signals to corresponding voltages for downstream processing. The resulting voltages are then fed into a microcontroller and the measured shift in resonant frequency is converted to a real-time glucose concentration.
BOPI
Sede Electrónica
